Edition:
United Kingdom

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

4.77USD
16 Aug 2019
Change (% chg)

$0.05 (+1.06%)
Prev Close
$4.72
Open
$4.75
Day's High
$4.84
Day's Low
$4.72
Volume
318,225
Avg. Vol
422,572
52-wk High
$5.02
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Achillion Reports Q2 Loss Per Share $0.14
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ACHILLION PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.14.ACHILLION PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2019 WAS $241.3 MILLION.ACHILLION PHARMACEUTICALS INC - EXPECTS NET-CASH SPEND FOR FULL YEAR OF 2019 TO BE APPROXIMATELY $85 MILLION.ACHILLION PHARMACEUTICALS - ACH-5228'S NEAR COMPLETE & SUSTAINED INHIBITION OF ALTERNATIVE PATHWAY & ITS TOLERABILITY SUPPORT US IND SUBMISSION Q419.  Full Article

Achillion Reports Positive Interim Data For Ach-4471 Phase 2 Combination Trial With Eculizumab At The New Era Of Aplastic Anemia And Pnh Meeting
Friday, 17 May 2019 

May 17 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS POSITIVE INTERIM DATA FOR ACH-4471 PHASE 2 COMBINATION TRIAL WITH ECULIZUMAB AT THE NEW ERA OF APLASTIC ANEMIA AND PNH MEETING.ACHILLION - ACH-4471 INCREASED HEMOGLOBIN AND NEARLY ELIMINATED NEED FOR TRANSFUSIONS IN PATIENTS WITH PNH BEING TREATED WITH C5 INHIBITOR, ECULIZUMAB.ACHILLION PHARMACEUTICALS INC - ACH-4471 WAS GENERALLY WELL TOLERATED WHEN ADDED TO ECULIZUMAB IN PATIENTS WITH PNH.ACHILLION PHARMACEUTICALS - LOOK FORWARD TO COMPLETING PHASE 2 TRIAL THIS SUMMER & FUTURE DISCUSSIONS WITH REGULATORY AUTHORITIES.ACHILLION PHARMACEUTICALS INC - HOPE TO INITIATE A PHASE 3 PNH COMBINATION TRIAL OF ACH-4471 WITH C5 INHIBITORS IN FIRST HALF OF 2020.  Full Article

Achillion Pharmaceuticals Reports Q1 Loss Per Share Of $0.14
Thursday, 9 May 2019 

May 9 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.14.  Full Article

Achillion Q3 Loss Per Share $0.12
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.ACHILLION PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.12.  Full Article

Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY.ACHILLION - ‍EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ISSUED POSITIVE OPINION ON ACH-4471 FOR ORPHAN STATUS IN EU FOR C3 GLOMERULOPATHY​ TREATMENT.  Full Article

Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.SEES FY 2018 LOSS PER SHARE $0.55 TO $0.58.JOSEPH TRUITT, CHIEF OPERATING OFFICER, PROMOTED TO PRESIDENT OF ACHILLION.SEEKING TO GENERATE ADDITIONAL DATASETS WITH ACH-4471 IN BOTH C3G AND PNH PROGRAMS IN 2018.RESTRUCTURING WILL REDUCE COMPANY'S WORKFORCE BY APPROXIMATELY 20% TO APPROXIMATELY 70 EMPLOYEES..ACHILLION - RESTRUCTURING PLAN EXPECTED TO DELIVER ABOUT $10 MILLION OF SAVINGS IN 2018 OVER 2017 EXPENSE LEVELS.FY2018 EARNINGS PER SHARE VIEW $-0.71 -- THOMSON REUTERS I/B/E/S.ACHILLION - DUE TO RESTRUCTURING, EXPECT RESEARCH AND DEVELOPMENT EXPENSES DURING 2018 WILL BE ABOUT $58 MILLION - $60 MILLION.QTRLY LOSS PER SHARE $0.17.Q4 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.  Full Article

Achillion Initiates Phase I First-In Study Of ACH-5228
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - COMPANY EXPECTS TO REPORT INTERIM CLINICAL DATA FROM STUDY DURING SECOND HALF OF 2018.  Full Article

Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY.ACHILLION PHARMACEUTICALS INC - INITIATED BIOAVAILABILITY STUDY EVALUATING EXTENDED-RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - INITIATION OF BIOAVAILABILITY STUDY OF EXTENDED RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.  Full Article

Achillion announces pricing of secondary offering of common stock
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces pricing of secondary offering of common stock.Says secondary public offering of 18.4 million common shares priced at $2.75per share.  Full Article

Achillion announces proposed secondary offering of common stock
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion announces proposed secondary offering of common stock.Achillion Pharmaceuticals Inc says ‍intends to offer for sale in an underwritten public offering 18.4 million shares of common stock of achillion​.Achillion Pharmaceuticals - existing stockholder of company, Johnson & Johnson Innovation-JJDC Inc will be making the offering of common stock.Achillion Pharmaceuticals Inc - ‍achillion will not sell any shares or receive any proceeds from offering​.  Full Article